Overview
Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers
Status:
Completed
Completed
Trial end date:
2012-09-01
2012-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidisPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Healthy, males or females, 21 to 55 years old.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
Exclusion Criteria:
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
(including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the
time of dosing).
Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment
with an investigational, prescription, or non-prescription drug